Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation

Autor(es)

Marcatto, Leiliane Rodrigues ; Sacilotto, Luciana ; da Costa Darrieux, Francisco Carlos ; Hachul, Denise Tessariol ; Scanavacca, Mauricio Ibrahim ; Krieger, Jose Eduardo ; Pereira, Alexandre Costa ; Junior Lima Santos, Paulo Caleb

• Tipo de documento: Artigo Científico
• Fonte: ONCOTARGET; v. 7, n. 34, p. 54194-54199, AUG 23 2016.
• Citações Web of Science: 3

Resumo

Background: Warfarin is the most prescribed oral anticoagulant used for preventing stroke in patients with atrial fibrillation. Time in the therapeutic range (TTR) has been accepted as the best method to evaluate the quality of warfarin therapy. The main aim of the present study was to evaluate the impact of variables on the time in the therapeutic range for warfarin therapy in patients with atrial fibrillation from a referral cardiovascular hospital. Methods: This retrospective study included 443 patients were included (190 patients with age < 65 years and 253 patients with age >= 65 years) from 2011 to 2014 and TTR was computed according to Rosendaal's method. Results: Patients with age >= 65 years had higher TTR value (67+/-22%) compared with patients with < 65 years (60+/-24%) (p = 0.004). In a linear regression model, only age >= 65 years emerged as a significant predictor of greater TTR values. In multivariate logistic regression model, the variable age = 65 years was associated with higher OR for having a TTR higher than the median value (OR = 2.17, p < 0.001). Conclusion: We suggest that the age influenced TTR through greater drug adherence. Strategies for increasing drug adherence might improve quality of warfarin anticoagulation. (AU)

• Processo FAPESP: 13/09295-3 - Avaliação farmacogenética para fármacos do sistema cardiovascular com foco na implementação
• Beneficiário: Paulo Caleb Júnior de Lima Santos
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores